Approval · Notice of Compliance 34612 · 2024
BISOPROLOL TABLETS: Notice of Compliance 34612
Issued December 24, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34612
- Date
- December 24, 2024
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BISOPROLOL TABLETS | 02554240 | Approved |
| BISOPROLOL TABLETS | 02554259 | Approved |
| BISOPROLOL TABLETS | 02495562 | Marketed |
| BISOPROLOL TABLETS | 02495570 | Marketed |
Medicinal ingredients
- BISOPROLOL FUMARATE 1.25 MG per TAB
- BISOPROLOL FUMARATE 2.5 MG per TAB
- BISOPROLOL FUMARATE 5 MG per TAB
- BISOPROLOL FUMARATE 10 MG per TAB